THC and CBD generally gain all the fame but breeders are now developing strains rich in other cannabinoids
Producers are constantly breeding new varieties of cannabis, and some of them try to create strains with unusual high concentrations of cannabinoids. Specifically, the breeding community is on the verge of commercializing cannabis strains rich in tetrahydrocannabivarin (THC-V), cannabidivarin (CBD-V) and cannabigerol (CBG).
These new strains with high levels of THC-V, CBD-V, and CBG are created through breeding techniques combined with extensive laboratory testing. This means that mother plants with known levels of cannabinoids are crossed and the seeds are collected and grown. Normally, some of the offspring will show higher levels of the desired cannabinoid than the parents. These products are crossed and the process continues over several generations. It's a laborious and time-consuming process, but it's the only way to create the high levels of cannabinoids you want.
It's also the same process that was used many years ago to create the first CBD-rich strains, those that contained 4% or more CBD in the dried buds. At the moment, we still do not know what the final level of THC-V and CBD-V will be in these new strains, but it could be around 2 to 7%, with a maximum target of 10%. Cannabigerol levels should be around 4% once stabilized.
Growers are constantly breeding new varieties of cannabis, and some of them are trying to create strains with high concentrations of unusual cannabinoids. The breeding community is very close to bringing to market cannabis strains rich in tetrahydrocannabivarin (THC-V), cannabidivarin (CBD-V), and cannabigerol (CBG). The first of these varieties was created last May at the Polytechnic University of Valencia.
As the name suggests, THC-V has a similar molecular structure to THC with some slight differences. Tetrahydrocannabivarin is psychoactive, and early indications suggest that THC-V may have the ability to enhance the euphoric effects of THC. So, this could be a cannabinoid that is of great interest to recreational users. Of course, medical users might find great use for THC-V. In fact, GW Pharmaceuticals is investing heavily in research into THC-V as a possible oral drug to treat diabetes.
Tetrahydrocannabivarin has a high boiling point, around 220 ° C. So your vaporizer may need to be set to a higher temperature to release it. For comparison, THC boils at around 160 ° C.
Cannabidivarin is a non-psychoactive cannabinoid, which means it won't lift you very high, and its chemical structure is very similar to that of CBD. It has been found naturally at reasonably high levels in some varieties of indica from northern India, near mountainous areas, as well as some varieties from Nepal. Some of the highest concentrations of CBD-V are found in the nepali hash . The ancients will remember the legendary Temple Balls, one of the most sought after hashish varieties in the past.
Today, CBD-V is already receiving a lot of medical attention from GW Pharmaceuticals, who are impressed with its anticonvulsant properties. Long-term medical research focuses on drugs antiepileptic for adults and children. Again, many questions about the function and effect of this cannabinoid remain unanswered. However, given that the big pharmaceutical companies are already investing heavily in CBD-V, it seems quite likely that the medical evidence for the effectiveness of CBD-V is mounting.
Cannabigerol, considered non-psychoactive, is the non-acidic version of cannabigerol acid (CBGA). Cannabigerolic acid is often thought of as the “parent cannabinoid,” which is the starting point from which other cannabinoids are created.
In most varieties of cannabis, a large part of the CBG is converted into other cannabinoids, usually THC or CBD. As a result, most strains of cannabis have less than 1% CBG in the plant at the time of harvest. However, selective breeding resulted in an increase in CBG levels of 2-3% in research varieties, and this increase could be further increased before the release of the first CBG variety. Ongoing research will confirm many of the medical benefits of CBG, but it could have potential uses as a neuroprotector, pain treatment, anxiety, anti-inflammatory, and antiseptic.
An exciting time for cannabis
No one really knows the full range of medical benefits that THCV, CBDV, and CBG could offer. While some research has been done on these newer cannabinoids, little is known about how they will interact, in high concentrations, with other cannabinoids. For example, will the new cannabinoids amplify the effects of other cannabinoids or will they neutralize them? Will the new cannabinoids be the most loved by medical users, or will they give recreational users new levels of satisfaction and enjoyment? Only time will tell.
CBD strains were just the first wave of new strains that were high in cannabinoids. Many have been surprised at the impact of CBD strains. It will therefore be fascinating to see how the new varieties of cannabinoids are finally received.
an article proposed by Maximum Yield